Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Notes Receivable: ¥0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688513 Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
91 GF Score
Price ¥54.63
GF Value ¥48.14
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Chengdu Easton Biopharmaceuticals Co Notes Receivable?

Chengdu Easton Biopharmaceuticals Co SHSE:688513 -6.74% 91 Notes Receivable is ¥0 Mil as of Mar. 2026. GuruFocus rates SHSE:688513 with a GF Score™ of 91/100 and a GF Value™ of ¥48.14 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Chengdu Easton Biopharmaceuticals Co's Notes Receivable for the quarter that ended in Mar. 2026 was ¥0 Mil.

Chengdu Easton Biopharmaceuticals Co Notes Receivable Related Terms

Chengdu Easton Biopharmaceuticals Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for Chengdu Easton Biopharmaceuticals Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chengdu Easton Biopharmaceuticals Co Notes Receivable Chart

Chengdu Easton Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Chengdu Easton Biopharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:688513
91GF Score
Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chengdu Easton Biopharmaceuticals Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ¥0 Mil mean?
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a Notes Receivable of ¥0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors.
Is Chengdu Easton Biopharmaceuticals Co's Notes Receivable too high?
Chengdu Easton Biopharmaceuticals Co's current Notes Receivable is ¥0 Mil. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's Notes Receivable compare to VRTX and REGN?
Chengdu Easton Biopharmaceuticals Co's Notes Receivable of ¥0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. Chengdu Easton Biopharmaceuticals Co's current Notes Receivable is ¥0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥48.14, compared to a current price of ¥54.63 — trading 13.5% above its estimated fair value. The current Notes Receivable is ¥0 Mil. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current Notes Receivable is ¥0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?

Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued. The current stock price of ¥54.63 is trading 13.5% above its estimated GF Value™ of ¥48.14. GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Modestly Overvalued.

Key valuation signals for SHSE:688513:

  • Notes Receivable: ¥0 Mil
  • GF Value™: ¥48.14 vs. price of ¥54.63 (13.5% above fair value)
  • GF Score™: 91/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengdu Easton Biopharmaceuticals Co Business Description

Address No. 8, Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
91GF Score

Get the complete analysis for SHSE:688513

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥54.63
Price
¥48.14
GF Value